These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 489770)

  • 1. Studies on the pharmacokinetics and pharmacodynamics of the beta-adrenergic blocking agent sotalol in normal man.
    Schnelle K; Klein G; Schinz A
    J Clin Pharmacol; 1979; 19(8-9 Pt 2):516-22. PubMed ID: 489770
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Pharmacokinetics and pharmacodynamics of the beta-receptor blocker sotalol].
    Limbourg P; Just H; Kersting F; Lang KF
    Verh Dtsch Ges Inn Med; 1977 Apr 17-21; 83():1690-4. PubMed ID: 347795
    [No Abstract]   [Full Text] [Related]  

  • 3. Relationship between pharmacokinetics and pharmacodynamics of the beta adrenergic blocking drug sotalol in dogs.
    Ishizaki T; Tawara K
    J Pharmacol Exp Ther; 1979 Nov; 211(2):331-7. PubMed ID: 501565
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Studies on the pharmacokinetics and effects of beta-adrenergic blocking agents, sotalol (author's transl)].
    Tawara K
    Hokkaido Igaku Zasshi; 1977 May; 52(3):245-59. PubMed ID: 914235
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Treatment of arterial hypertension with sotalol, a beta-blocker (author's transl)].
    Klein G; Schnelle K; Schinz A; Oberländer V
    Dtsch Med Wochenschr; 1977 Apr; 102(15):563-9. PubMed ID: 849711
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetics and pharmacodynamics in young normal and elderly hypertensive subjects: a study using sotalol as a model drug.
    Ishizaki T; Hirayama H; Tawara K; Nakaya H; Sato M; Sato K
    J Pharmacol Exp Ther; 1980 Jan; 212(1):173-81. PubMed ID: 6101341
    [No Abstract]   [Full Text] [Related]  

  • 7. Pharmacokinetics of sotalol during pregnancy.
    O'Hare MF; Leahey W; Murnaghan GA; McDevitt DG
    Eur J Clin Pharmacol; 1983; 24(4):521-4. PubMed ID: 6861867
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Propranolol and sotalol metabolism after a drinking party.
    Sotaniemi EA; Anttila M; Rautio A; Stengård J; Saukko P; Järvensivu P
    Clin Pharmacol Ther; 1981 Jun; 29(6):705-10. PubMed ID: 7226702
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetics of sotalol after chronic administration to patients with renal insufficiency.
    Berglund G; Descamps R; Thomis JA
    Eur J Clin Pharmacol; 1980 Oct; 18(4):321-6. PubMed ID: 7439252
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of the beta-adrenoceptor blocking agent sotalol on CNS: sleep, EEG, and psychophysiological parameters.
    Bender W; Greil W; Rüther E; Schnelle K
    J Clin Pharmacol; 1979; 19(8-9 Pt 2):505-12. PubMed ID: 226565
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetics of propranolol and sotalol in hyperthyroidism.
    Aro A; Anttila M; Korhonen T; Sundquist H
    Eur J Clin Pharmacol; 1982; 21(5):373-7. PubMed ID: 7075642
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of nebivolol, atenolol and propranolol on in vivo cardiovascular and metabolic responses to isoproterenol in dogs.
    Bowden CR; Marchione CS
    J Pharmacol Exp Ther; 1989 Nov; 251(2):599-605. PubMed ID: 2572694
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Chronopharmacokinetics of beta-receptor blocking drugs of different lipophilicity (propranolol, metoprolol, sotalol, atenolol) in plasma and tissues after single and multiple dosing in the rat.
    Lemmer B; Winkler H; Ohm T; Fink M
    Naunyn Schmiedebergs Arch Pharmacol; 1985 Jul; 330(1):42-9. PubMed ID: 2864639
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Single-dose kinetics of oral propranolol, metoprolol, atenolol, and sotalol: relation to lipophilicity.
    Ochs HR; Greenblatt DJ; Arendt RM; Schäfer-Korting M; Mutschler E
    Arzneimittelforschung; 1985; 35(10):1580-2. PubMed ID: 2866772
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical pharmacokinetics of beta-adrenoreceptor blocking drugs.
    Johnsson G; Regàrdh CG
    Clin Pharmacokinet; 1976; 1(4):233-63. PubMed ID: 13958
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparative beta-blocking activities and electrophysiologic actions of racemic sotalol and its optical isomers in anesthetized dogs.
    Gomoll AW; Bartek MJ
    Eur J Pharmacol; 1986 Dec; 132(2-3):123-35. PubMed ID: 2880732
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sotalol intoxication, two patients with concentration-effect relationships.
    Neuvonen PJ; Elonen E; Tarssanen L
    Acta Pharmacol Toxicol (Copenh); 1979 Jul; 45(1):52-7. PubMed ID: 474159
    [TBL] [Abstract][Full Text] [Related]  

  • 18. High isoproterenol doses are required to activate beta3-adrenoceptor-mediated functions in dogs.
    Pelat M; Verwaerde P; Galitzky J; Lafontan M; Berlan M; Senard JM; Montastruc JL
    J Pharmacol Exp Ther; 2003 Jan; 304(1):246-53. PubMed ID: 12490598
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetics of the -adrenergic blocker sotalol in dogs.
    Schnelle K; Garrett ER
    J Pharm Sci; 1973 Mar; 62(3):362-75. PubMed ID: 4144183
    [No Abstract]   [Full Text] [Related]  

  • 20. Comparative antihypertensive effects and tissue distribution of beta adrenergic blocking drugs.
    Garvey HL; Ram N
    J Pharmacol Exp Ther; 1975 Jul; 194(1):220-33. PubMed ID: 1151751
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.